ERBB2 and breast carcinoma: Each subtype has distinct molecular characteristics and although individual patient prognosis varies, patients with the hormone receptor-positive, HER2-negative (HR+/HER2−) subtype generally have a more favorable prognosis whereas those with hormone receptor-negative (HR−) breast cancer have a poor prognosis [2–4].